Mori et al.
Human trial · 30 participants
An early signal in adults with mild cognitive impairment
The mushroom group had higher scores on one cognitive scale during the trial. Their scores declined after supplementation stopped.
What was tested & what to keep in mind
- Design
- Double-blind, placebo-controlled trial in 30 Japanese adults aged 50–80 with mild cognitive impairment.
- Preparation & duration
- Tablets supplying approximately 3 g of dried mushroom powder daily for 16 weeks, followed by four weeks without treatment.
- Limitations
- A small, selected group and one cognitive scale. This does not establish dementia prevention, a treatment benefit for everyone, or the effect of eating fresh mushrooms.
Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.


